Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.
Checked against the public recordLast updated Mar 7, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- SCRI Development Innovations, LLC
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients must have had NSCLC. * Patients must have received erlotinib (single-agent) for six months or longer for NSCLC in the second/third line setting or as maintenance therapy. * Patients must have tissue available for EGFR-mutation status testing (if not previously performed) or EGFR-mutation status test results available. * Patients must have tissue available for exploratory genetic analysis. * Patients must have all clinical information, treatment response data and outcomes data available for review. * Patients must be deceased.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Tennessee Oncology, PLLCNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 7, 2016. Always confirm current availability with the study team.